PeptidePedia The community reference

Contributions of ForestPlotFinn

User contributions·43 logged edits·page 1 of 1

Contributions by ForestPlotFinn, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 10,366 edits includes activity predating the current log.

  1. 11:15, 10 Jun 2026 (diff | hist) Talk:STEP trial programme 674 +140 /* The mean describes nobody */ new section
  2. 11:10, 21 May 2026 (diff | hist) Talk:Dulaglutide 537 +242 /* REWIND population */ new section
  3. 08:50, 15 May 2026 (diff | hist) Talk:GLP-1 receptor 885 +163 /* Heart-rate figure */ reply
  4. 08:41, 8 May 2026 (diff | hist) Talk:Trial data comparison 1,033 +120 /* Cross-trial tabulation and the estimand problem */ reply
  5. 10:22, 6 May 2026 (diff | hist) Talk:Trial data comparison 400 +461 /* Cross-trial tabulation and the estimand problem */ new section
  6. 13:35, 2 May 2026 (diff | hist) Talk:Orforglipron 611 +228 /* Cross-trial comparison in the last section */ reply
  7. 22:49, 30 Apr 2026 (diff | hist) GLP-1 receptor agonist 11,264 ±0 m expand §Material obtained outside licensed supply
  8. 10:15, 30 Apr 2026 (diff | hist) Talk:HOMA-IR 537 +180 /* Population versus individual */ new section
  9. 13:15, 9 Mar 2026 (diff | hist) Talk:Placebo-adjusted effect 611 +130 /* Placebo response is only one component */ reply
  10. 03:49, 4 Mar 2026 (diff | hist) Syringe dead space 20,340 +55 ce
  11. 13:40, 24 Feb 2026 (diff | hist) Talk:PeptideMeter 611 +213 /* Lower bound on variability */ reply
  12. 09:52, 18 Feb 2026 (diff | hist) Resin cleavage 4,310 ±0 add the cross-link to the temperature-excursion article
  13. 13:20, 6 Feb 2026 (diff | hist) Talk:Adverse effects of GLP-1 receptor agonists 611 +117 /* Placebo-arm nausea */ reply
  14. 13:25, 26 Jan 2026 (diff | hist) Talk:SURPASS trial programme 611 +149 /* Cross-trial comparison of SURMOUNT and STEP */ reply
  15. 13:10, 24 Jan 2026 (diff | hist) Talk:Intention-to-treat analysis 611 +109 /* Adherence in the placebo arm */ reply
  16. 13:15, 19 Jan 2026 (diff | hist) Talk:SELECT trial 611 +119 /* Early curve separation */ reply
  17. 12:18, 12 Jan 2026 (diff | hist) Talk:Semaglutide 611 +173 /* Weight-loss figure in the lead */ reply
  18. 06:35, 27 Nov 2025 (diff | hist) SURPASS trial programme 5,078 ±0 expand §Constituent trials
  19. 01:00, 24 Nov 2025 (diff | hist) TRIUMPH trial programme 4,703 ±0 m add the missing-data handling method
  20. 21:35, 13 Oct 2025 (diff | hist) Resin cleavage 4,310 ±0 state the residual-moisture target with the method it is measured by
  21. 22:47, 11 Oct 2025 (diff | hist) Beyond-use date 21,165 +676 alphabetise the see-also list
  22. 10:46, 5 Sep 2025 (diff | hist) Amylin receptor agonist 5,245 +280 m add the peptide length to the infobox
  23. 02:55, 3 Aug 2025 (diff | hist) Number needed to treat 4,498 ±0 expand §Number needed to harm
  24. 11:59, 4 Jul 2025 (diff | hist) Fmoc chemistry 4,618 ±0 m attribute the stability figure to the study and its duration
  25. 09:52, 25 Jun 2025 (diff | hist) Talk:Trial data comparison 959 +236 /* Should the bars be there at all? */ reply
  26. 18:19, 22 Apr 2025 (diff | hist) SURMOUNT trial programme 3,589 +30 state that the trial has reported but is not yet peer-reviewed
  27. 10:53, 19 Apr 2025 (diff | hist) Grey market 3,184 +579 add the customs-detention point as a logistics fact, sourced
  28. 19:09, 2 Mar 2025 (diff | hist) SUSTAIN trial programme 4,187 +18 m split the results table so the two doses are separate rows
  29. 10:02, 23 Feb 2025 (diff | hist) Underfilling 2,520 +32 m state what the certificate actually carries, field by field
  30. 21:27, 20 Feb 2025 (diff | hist) Vial filling and stoppering 3,667 +312 m close an unbalanced quotation mark
  31. 13:20, 29 Jan 2025 (diff | hist) Placebo-adjusted effect 2,887 +34 expand §Where the adjustment is not enough
  32. 11:05, 29 Jan 2025 (diff | hist) SELECT trial 4,206 +29 m rm the survival claim — no mortality endpoint was pre-specified
  33. 10:13, 6 Jan 2025 (diff | hist) Batch number 3,490 +113 m expand §Consistency checks
  34. 05:44, 23 Nov 2024 (diff | hist) TRIUMPH trial programme 2,837 ±0 split overlong sentence
  35. 06:23, 12 Nov 2024 (diff | hist) Number needed to treat 2,280 +296 m copyedit
  36. 18:13, 23 Oct 2024 (diff | hist) Intention-to-treat analysis 2,691 ±0 m expand §Why analysing as treated fails
  37. 09:48, 26 Sep 2024 (diff | hist) LEADER trial 1,964 ±0 m convert the endpoint list to a table for comparability
  38. 10:08, 17 Sep 2024 (diff | hist) Solid-phase peptide synthesis 2,718 +108 correct the eutectic temperature — source gives a range
  39. 11:48, 16 Aug 2024 (diff | hist) Chinese Peptide Company 2,675 +457 typo
  40. 01:24, 16 Aug 2024 (diff | hist) High-performance liquid chromatography 3,179 +270 m expand §What the chromatogram reports
  41. 21:36, 2 Aug 2024 (diff | hist) SUSTAIN trial programme 1,946 +732 add the run-in period, which changes how the baseline reads
  42. 11:30, 20 Jul 2024 (diff | hist) Reverse-phase HPLC 2,305 ±0 m add the plate-count expression and define its terms
  43. 17:08, 3 Jul 2024 (diff | hist) Solid-phase peptide synthesis 1,893 ±0 expand §Support and linker